|本期目录/Table of Contents|

[1]梁开地,缑文斌,莫居容.肺癌组织中细胞角蛋白18的表达及与预后的相关性[J].中华肺部疾病杂志,2023,(05):688-690.[doi:10.3877/cma.j.issn.1674-6902.2023.05.021]
点击复制

肺癌组织中细胞角蛋白18的表达及与预后的相关性(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年05期
页码:
688-690
栏目:
出版日期:
2023-10-20

文章信息/Info

Title:
-
作者:
梁开地; 缑文斌; 莫居容
571500 海口,万宁市人民医院病理科
Author(s):
-
关键词:
支气管肺癌;  癌组织;  细胞角蛋白18;  预后
Keywords:
-
分类号:
R734.2
DOI:
10.3877/cma.j.issn.1674-6902.2023.05.021
摘要:
目的 分析肺癌组织细胞角蛋白18(cytokeratin 18, CK18)的表达及与预后的相关性。方法 选取2019年1月至2020年12月我院收治的97例肺癌患者为对象,采用免疫组织化学染色法检测癌组织及配对癌旁组织中CK18表达; 采用RT-PCR检测CK18 mRNA相对表达量。Kaplan-Meier曲线和COX比例风险回归分析肺癌预后情况。结果 癌组织CK18高表达51例(52.58%),高于癌旁组织15例(15.46%)(P<0.05)。癌组织CK18 mRNA相对表达量为(2.12±0.71),高于癌旁组织(0.67±0.21)(P<0.05)。COX多因素分析显示,TNM分期、远处转移、淋巴结转移、CK18高表达是肺癌低OS和低PFS的影响因素,化疗是保护因素(P<0.05)。97例中接受化疗41例、未接受化疗56例,CK18高表达者的总体生存期(OS)和无进展生存期(PFS)低于CK18低表达者(P<0.05)。结论 肺癌组织CK18表达水平升高,癌组织CK18高表达与肺癌患者不良生存预后有关,CK18可能成为肺癌的生物标志物。
Abstract:
-

参考文献/References:

1 吴国明, 钱桂生. 非小细胞肺癌靶向治疗研究进展及新理念[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(4): 405-408.
2 Kuburich NA, den Hollander P, Pietz JT, et al. Vimentin and cytokeratin: Good alone, bad together[J]. Semin Cancer Biol, 2022, 86(3): 816-826.
3 Yip TC, Lyu F, Lin H, et al. Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future[J]. Clin Mol Hepatol, 2023, 29(l): 171-183.
4 Li YP, Jia XP, Jiang YQ, et al. Differential expression of cytokeratin 14 and 18 in bladder cancer tumorigenesis[J]. Exp Biol Med(Maywood), 2018, 243(4): 344-349.
5 Yang J, Gao S, Xu J, et al. Prognostic value and clinicopathological significance of serum- and tissue-based cytokeratin 18 express level in breast cancer: a meta-analysis[J]. Biosci Rep, 2018, 38(2): BSR20171145.
6 Huang Y, Yang L, Lin Y, et al. Prognostic value of non-invasive serum Cytokeratin 18 detection in gastrointestinal cancer: a meta-analysis[J]. J Cancer, 2019, 10(20): 4814-4823.
7 Zhang B, Wang J, Liu W, et al. Cytokeratin 18 knockdown decreases cell migration and increases chemosensitivity in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2016, 142(12): 2479-2487.
8 Liu Q, Qiao M, Lohinai Z, et al. CCL19 associates with lymph node metastasis and inferior prognosis in patients with small cell lung cancer[J]. Lung Cancer, 2021, 162: 194-202.
9 周 宇. 肺癌患者癌组织中SHIP2、PLEK2蛋白表达水平及其临床预后意义[J]. 实用癌症杂志, 2022, 38(2): 187-191.
10 Saikawa H, Nagashima H, Cho K, et al. Relationship between Trace Element in Tumor and Prognosis in Lung Cancer Patients[J]. Medicina(Kaunas), 2021, 57(3): 209.
11 Nooreldeen R, Bach H. Current and future fevelopment in lung cancer diagnosis[J]. Int J Mol Sci, 2021, 22(16): 8661.
12 Bade BC, Dela Cruz CS. Lung cancer 2020: Epidemiology, etiology, and prevention[J]. Clin Chest Med, 2020, 41(1): 1-24.
13 王居鹏. 角蛋白18的功能及在肿瘤诊疗中的研究应用[J]. 天津医科大学学报, 2022, 28(6): 691-695.
14 Korver S, Bowen J, Pearson K, et al. The application of cytokeratin-18 as a biomarker for drug-induced liver injury[J]. Arch Toxicol, 2021, 95(11): 3435-3448.
15 Lim Y, Ku NO. Revealing the roles of Keratin 8/18-associated signaling proteins involved in the development of hepatocellular carcinoma[J]. Int J Mol Sci, 2021, 22(12): 6401.
16 师锐赞, 牛亚楠, 高 宇, 等. 细胞角蛋白18下调增加非肌肉肌球蛋白ⅡA表达促进乳腺癌转移[J]. 中国药理学通报, 2022, 38(6): 861-865.
17 Shi R, Liu L, Wang F, et al. Downregulation of cytokeratin 18 induces cellular partial EMT and stemness through increasing EpCAM expression in breast cancer[J]. Cell Signal, 2020, 76: 109810.
18 Menz A, Weitbrecht T, Gorbokon N, et al. Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors[J]. Mol Med, 2021, 27(1): 16.
19 Singh Bhangu J, Macher-Beer A, Schimek V, et al. Circulating caspase-cleaved cytokeratin 18 correlates with tumour burden and response to therapy in patients with colorectal cancer liver metastasis[J]. Clin Chim Acta, 2023, 538: 53-59.
20 Sirni? P, V?yrynen JP, Mutt SJ, et al. Systemic inflammation is associated with circulating cell death released keratin 18 fragments in colorectal cancer[J]. Oncoimmunology, 2020, 9(1): 1783046.
21 Shi R, Wang C, Fu N, et al. Downregulation of cytokeratin 18 enhances BCRP-mediated multidrug resistance through induction of epithelial-mesenchymal transition and predicts poor prognosis in breast cancer[J]. Oncol Rep, 2019, 41(5): 3015-3026.
22 Hendawy SR, Mansour M, Hamed M, et al. Serum cytokeratin 18 as a potential early marker for chemotherapy response in breast cancer patients: A prospective study[J]. Asian Pac J Cancer Prev, 2023, 24(3): 969-975.
23 Lorente L. New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma[J]. World J Gastroenterol, 2018, 24(37): 4230-4242.
24 López-Sánchez GN, Montalvo-Javé E, Domínguez-Perez M, et al. Hepatic mir-122-3p, mir-140-5p and mir-148b-5p expressions are correlated with cytokeratin-18 serum levels in MAFLD[J]. Ann Hepatol, 2022, 27(6): 100756.
25 Sears CR, Mazzone PJ. Biomarkers in lung cancer[J]. Clin Chest Med, 2020, 41(1): 115-127.

备注/Memo

备注/Memo:
基金项目: 海南省医药卫生科研项目(19A200093)
更新日期/Last Update: 2023-10-20